Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

Indication Sought for Breakthrough Pain Associated with Chronic Pain

Conditions in Patients Who are Already Taking Opioid Medications

Around-the-Clock

FRAZER, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate- to-severe intensity, and relatively short duration. According to a study published in the August 2006 issue of The Journal of Pain, up to 74 percent of patients with non-cancer chronic pain conditions treated for persistent pain, such as chronic low back and chronic neuropathic pain, will experience breakthrough pain. Currently FENTORA is approved for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent pain.

"The clinical trials supporting this submission mark the first time a pain medication has been evaluated as a treatment for breakthrough pain associated with serious chronic pain conditions other than cancer," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We look forward to working with FDA to broaden the use of FENTORA to opioid tolerant patients with unresolved debilitating breakthrough pain."

The FENTORA sNDA includes data from three randomized, placebo-controlled clinical trials and one long-term open-label safety study with a total of 941 opioid tolerant patients. The patients in the FENTORA sNDA trials were treated for up to 18 months and had a broad range of underlying chronic pain conditions, including chronic low back and chronic neuropathic pain. In the randomiz
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CANTON, Mass. and NEW ORLEANS ... commercial leader in the field of regenerative medicine, presented ... expert economists from Analysis Group (a leading health economics ... that diabetic foot ulcers (DFU) and venous leg ulcers ... The results of this research, which reveal annual ...
(Date:5/22/2013)... 2013 Mold remediation could take a toll ... is a way to cut down the process' expense. And ... post the details of a method how to kill ... could be prevented, My Cleaning Products said. But in case ... a mold remediation must then be promptly implemented as it ...
(Date:5/22/2013)... May 22, 2013 A recent study from ... on athletes to find that those who took probiotics were ... results from the study showed that in extreme heat conditions, ... for their adult acne treatment explains what this ... it may help their skin condition. , While researchers ...
(Date:5/21/2013)... , May 21, 2013  On May 9, ... ), the global business advisory firm dedicated to ... (the "Company"), announced that it has combined the ... formerly included within the Corporate Finance/Restructuring segment with ... to form a single integrated practice whose financial ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) (the "Company") ... per basic and diluted share for the quarter ended ... basic and diluted share for the,comparable period in 2007. ... was $2.0 million in the first quarter of 2008, ...
... PITTSBURGH, May 7 Mylan Inc. (NYSE: MYL ... approval,from the U.S. Food and Drug Administration (FDA) for ... 0.25 mg,(base), 0.5 mg (base), 1 mg (base), 2 ... mg (base)., Ropinirole Hydrochloride Tablets are the generic ...
... $17 ... Million, TUCSON, Ariz., ... it has signed a letter of intent in,which Microbix Biosystems will acquire ... is an FDA-approved,thrombolytic, or clot-dissolving agent, indicated for the treatment of,acute massive ...
Cached Biology Technology:Oncothyreon Reports First Quarter 2008 Financial Results 2Oncothyreon Reports First Quarter 2008 Financial Results 3Oncothyreon Reports First Quarter 2008 Financial Results 4Oncothyreon Reports First Quarter 2008 Financial Results 5ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 2ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 3ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 4
(Date:5/21/2013)... for a long time that some creatures evolve more ... for plants. But it may be that height plays ... and the U. S. National Evolutionary Synthesis Center. ... in the journal Nature Communications , Lanfear and ... Drawing from a database of global patterns in plant ...
(Date:5/21/2013)... in the body, stem cells in the blood ... into mature immune cells that can fight off ... these cell populations, potentially leading to the development ... a team of researchers led by biologists at ... that, in mouse models, the molecule microRNA-146a (miR-146a) ...
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
... January 18, 2011 Using chemical compounds found in a ... ultraviolet light, a Scripps Research Institute team has created a ... biomedical potential. Already, one of the compounds has shown great ... With the report of their work scheduled to ...
... Soy protein,s ability to lower total and ... been extensively studied, but the mechanism whereby soy ... published in the Journal of Clinical Lipidology ... total cholesterol and non-HDL (non-high-density lipoprotein) cholesterol significantly ...
... EAST LANSING, Mich. The downsides of China,s explosive ... now are joined by an upside: Better environmental citizens. ... and leadership when considering environmental behavior in China,s cities. ... Environmental Conservation , scientists at the Center for ...
Cached Biology News:Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein 2Big city life may make residents lean toward green, study says 2
Cytofix/Cytoperm Kit 250 Tests...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: